[go: up one dir, main page]

EA201100126A1 - Нафтиридиноны в качестве ингибиторов протеинкиназ - Google Patents

Нафтиридиноны в качестве ингибиторов протеинкиназ

Info

Publication number
EA201100126A1
EA201100126A1 EA201100126A EA201100126A EA201100126A1 EA 201100126 A1 EA201100126 A1 EA 201100126A1 EA 201100126 A EA201100126 A EA 201100126A EA 201100126 A EA201100126 A EA 201100126A EA 201100126 A1 EA201100126 A1 EA 201100126A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
proteinkinaz
nafthyridinoes
inhibitors
naphthyridinone
Prior art date
Application number
EA201100126A
Other languages
English (en)
Inventor
Юфан Сяо
Сяолин Чэнь
Сриниваса Р. Карра
Бейард Р. Хак
Аманда Э. Саттон
Андреас Гоутопоулос
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201100126A1 publication Critical patent/EA201100126A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаны соединения - производные нафтиридинона, которые ингибируют ферменты Аурора киназы, а также фармацевтические композиции, которые содержат эти соединения, и способы их синтеза. Такие соединения пригодны для лечения пролиферативных заболеваний, возникающих вследствие нерегулируемых и/или нарушенных Аурора киназ, таких как злокачественные новообразования, псориаз, вирусные и бактериальные инфекции, воспалительные и аутоиммунные заболевания.
EA201100126A 2008-07-03 2009-06-29 Нафтиридиноны в качестве ингибиторов протеинкиназ EA201100126A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13401808P 2008-07-03 2008-07-03
PCT/US2009/049035 WO2010002779A2 (en) 2008-07-03 2009-06-29 Naphthyridininones as aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201100126A1 true EA201100126A1 (ru) 2011-08-30

Family

ID=41466544

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100126A EA201100126A1 (ru) 2008-07-03 2009-06-29 Нафтиридиноны в качестве ингибиторов протеинкиназ

Country Status (13)

Country Link
US (1) US20110269758A1 (ru)
EP (1) EP2291376A2 (ru)
JP (1) JP2011526912A (ru)
KR (1) KR20110025856A (ru)
CN (1) CN102083831B (ru)
AU (1) AU2009267161B2 (ru)
BR (1) BRPI0914936A2 (ru)
CA (1) CA2727103A1 (ru)
EA (1) EA201100126A1 (ru)
IL (1) IL210377A (ru)
MX (1) MX2010013842A (ru)
WO (1) WO2010002779A2 (ru)
ZA (1) ZA201008878B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012502391A1 (en) * 2010-06-28 2013-02-11 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
CN102408426B (zh) * 2011-09-14 2013-07-10 湖南有色凯铂生物药业有限公司 取代的芳香脲类化合物及其作为抗癌药物的应用
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
CA3033752C (en) * 2016-08-15 2022-05-31 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
KR102055660B1 (ko) * 2018-03-07 2019-12-13 경상대학교산학협력단 나프타미도-페닐아잔디일 유도체, 이를 포함하는 우라닐 이온 검출용 조성물 및 이를 이용한 우라닐 이온 검출 방법
KR102747104B1 (ko) * 2019-02-18 2024-12-27 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
MX2023007670A (es) * 2020-12-29 2023-07-07 Txinno Bioscience Inc Nuevo derivado de naftiridinona que tiene actividad inhibidora contra la ectonucleotido pirofosfatasa -fosfodiesterasa y uso del mismo.
CN116669726A (zh) * 2020-12-29 2023-08-29 谛希诺生物科技有限公司 对外核苷酸焦磷酸酶-磷酸二酯酶具有抑制活性的新颖的萘啶酮衍生物及其用途
KR102720206B1 (ko) * 2020-12-29 2024-10-21 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
WO2024206339A1 (en) * 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127252D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
NZ334125A (en) * 1996-09-25 2000-10-27 Zeneca Ltd Quinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
CZ20021009A3 (cs) * 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
JP4105947B2 (ja) * 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なトリアゾール化合物
CN1308310C (zh) * 2000-10-20 2007-04-04 卫材R&D管理有限公司 含氮芳环衍生物
EP1578755B1 (en) * 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
AU2004212957A1 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
US20070066632A1 (en) * 2005-03-25 2007-03-22 Scios, Inc. Fused bicyclic inhibitors of TGFbeta
JP2008534479A (ja) * 2005-03-25 2008-08-28 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｃｖの複素二環式阻害剤
ES2378473T3 (es) * 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales

Also Published As

Publication number Publication date
US20110269758A1 (en) 2011-11-03
MX2010013842A (es) 2011-01-14
KR20110025856A (ko) 2011-03-11
JP2011526912A (ja) 2011-10-20
AU2009267161A1 (en) 2010-01-07
AU2009267161B2 (en) 2014-11-06
IL210377A (en) 2015-03-31
CN102083831B (zh) 2014-09-03
ZA201008878B (en) 2012-02-29
WO2010002779A2 (en) 2010-01-07
IL210377A0 (en) 2011-03-31
CN102083831A (zh) 2011-06-01
BRPI0914936A2 (pt) 2015-10-20
CA2727103A1 (en) 2010-01-07
EP2291376A2 (en) 2011-03-09
WO2010002779A3 (en) 2011-03-03
HK1156611A1 (en) 2012-06-15

Similar Documents

Publication Publication Date Title
EA201100450A1 (ru) Макроциклические пирамидины в качестве ингибиторов протеинкиназы
EA201100126A1 (ru) Нафтиридиноны в качестве ингибиторов протеинкиназ
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201691142A1 (ru) Ингибиторы мек и способы их применения
MX382352B (es) Compuestos de heteroarilo y usos de los mismos.
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201070247A1 (ru) Ингибиторы протеасом
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
EA201171454A1 (ru) N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
EA200970738A1 (ru) Ингибиторы активности akt
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения